<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of" exact="China" post="in late December 2019 and identified as a novel"/>
 <result pre="diagnosis of SARS-CoV-2 infection [6]. As of 19 April 2020," exact="the US" post="Food and Drug Administration had approved more than 37"/>
 <result pre="[47]. According to the report, an individual with COVID-19 in" exact="the USA" post="exhibited substantial improvement when treated with remdesivir intravenously [48],"/>
 <result pre="remdesivir treatment. At present, four clinical trials recruiting patients in" exact="the USA" post="and two other trials enrolled only in China have"/>
 <result pre="in the USA and two other trials enrolled only in" exact="China" post="have been registered on ClinicalTrials.gov: NCT04257656 (serious disease) and"/>
 <result pre="[55]. Ivermectin Ivermectin is a broad-spectrum antiparasitic drug approved by" exact="the US" post="Food and Drug Administration. In recent years, it has"/>
 <result pre="spread of viruses among populations. Molecular based laboratory testing Currently," exact="the US" post="CDC recommended strategy for identifying individuals with COVID-19 is"/>
</results>
